Dr Lalchandani Labs Defers Board Meeting On Rights Issue Terms

Dr Lalchandani Labs Ltd announced that its board meeting scheduled for December 22, 2025, to determine the final terms of its proposed rights issue has been deferred. The rights issue, valued at ₹433.31 lakh, was approved earlier by the board on December 15, 2025, and was intended to raise funds through equity shares of ₹10 face value for eligible shareholders.

The company clarified that the deferment was necessary as the in-principle approval from BSE Limited had not yet been received. The meeting was expected to finalize key aspects such as the record date, issue price, and entitlement ratio. Dr Lalchandani Labs assured stakeholders that the process will resume once regulatory approvals are in place, ensuring compliance with SEBI and exchange requirements.

Key Highlights

• Board meeting scheduled for December 22, 2025 deferred
• Reason: Non-receipt of in-principle approval from BSE Limited
• Rights issue size: ₹433.31 lakh through equity shares of ₹10 face value
• Earlier board approval granted on December 15, 2025
• Terms including record date, issue price, and entitlement ratio remain pending
• Company assures compliance and will reschedule once approvals are secured

Sources: ScanX News, BSE Corporate Filing, Rediff Money